[2P-0724] ANGPTL1 Antagonizes MET Receptor Activity to Repress Sorafenib Resistance and Cancer Stemness in Hepatocellular Carcinoma Cells

〇Shu-Ting Yang¹、Hsin-An Chen^2,3、Tsang-Chih Kuo⁴、Chi-Feng Tseng^1,5、Jui-Ti Ma¹、Chia-Jui Yen⁶、Ching-Yao Yang⁷、Shian-Ying Sung⁸、Jen-Liang Su^1,9,10,11 (1.National Institute of Cancer Research, National Health Research Institutes, Taiwan、2.Department of Surgery, Division of General Surgery, Shuang Ho Hospital, Taipei Medical University, Taiwan、3.Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taiwan、4.Institute of Biochemical Sciences, College of Life Science, National Taiwan University, Taiwan、5.Graduate Program of Biotechnology in Medicine College of Life Science, National Tsing Hua University, Taiwan、6.Division of Hematology-Oncology, Department of Internal Medicine, National Cheng Kung University Hospital, Taiwan、7.Department of Surgery, National Taiwan University Hospital, Taiwan、8.Program for Translational Medicine, College of Medical Science and Technology, Taipei Medical University, Taiwan.、9.Graduate Institute of Cancer Biology, China Medical University, Taiwan、10.Center for Molecular Medicine, China Medical University Hospital, Taiwan、11.Department of Biotechnology, Asia University, Taiwan)

Angiopoietin-like protein 1, Sorafenib Resistance, Liver Cancer Stem Cells, Slug